Why the study?
Does the BVDS regimen improve response rates in patients with advanced Hodgkin disease resistant to MOPP?
Does the BVDS regimen improve response rates in patients with advanced Hodgkin disease resistant to MOPP?
The BVDS regimen demonstrated a 50% response rate in patients with MOPP-resistant advanced Hodgkin disease, suggesting it may be an effective alternative therapy.
Should not alter management of MOPP-resistant Hodgkin disease; leaves open whether BVDS offers benefit pending controlled trials.
A new four-drug combination chemotherapeutic regimen (BVDS) was used in the treatment of advanced Hodgkin disease resistant to MOPP (mechlorethamine hydrochloride, vincristine sulfate, procarbazine hydrochloride, and prednisone). The BVDS regimen, consisting of 12 cycles of bleomycin sulfate, vinblastine sulfate, doxorubicin hydrochloride (Adriamycin), and streptozocin (streptozotocin), was administered to ten patients. Responses were seen in five (50%) of these patients. Complete remissions occurred in three (30%). These results suggest that BVDS is an effective alternative regimen to MOPP, and may be of benefit not only to patients resistant to MOPP, but also to newly-diagnosed patients with advanced hodgkin disease when combined sequentially with MOPP.
No takes yet. Share an insight, caveat, or question.
Vincent Vinciguerra (1977) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: